Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion type Assertion NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_head.
- NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion description "[The observed statistically significant associations included a decreased CRC risk for TGFBR1 IVS7G+24A minor allele carriers (odds ratio (OR): 0.72, 95% confidence interval (CI): 0.53-0.97), less aggressive tumors with Dukes' stage A+B for carriers of LTBP4 Thr750Ala and BAMBI T-779A minor alleles (OR: 0.58, 95%CI: 0.36-0.93 and OR: 0.51, 95%CI: 0.29-0.89, respectively) and worse survival for FURIN C-229T heterozygotes (hazard ratio: 1.63, 95%CI: 1.08-2.46).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_provenance.
- NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion evidence source_evidence_literature NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_provenance.
- NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion SIO_000772 19998449 NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_provenance.
- NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion wasDerivedFrom befree-20150227 NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_provenance.
- NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_assertion wasGeneratedBy ECO_0000203 NP605444.RABDq4toP8XMlcSAbGW0YqjLU4cn5rnLzgpNxgM3_o3eI130_provenance.